BOS 421
Alternative Names: BOS-421; GSK-3502421Latest Information Update: 22 Mar 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories; Neuroprotectants; Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple sclerosis
Most Recent Events
- 22 Mar 2023 Phase-I clinical trials in Multiple sclerosis in USA (PO) (Boston Pharmaceuticals pipeline, March 2023)
- 18 Mar 2021 GlaxoSmithKline signs license and option agreement with Boston Pharmaceuticals for GSK 3502421
- 18 Mar 2021 Preclinical trials in Neurological disorders in United Kingdom (PO) before March 2021